Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
West Cancer Center
« back to all trials
View Trial On ClinicalTrials.gov
PANCREAS: Metastatic: 2nd Line; Phase 1; "D4884C00001 PDAC"

A Phase II, Milti-center, Open-Label Study of Tremelimumab Monotherapy in Patients WIth Advanced Solid Tumors

Title
AstraZeneca D4884C00001 PDAC
Study Title
A Phase II, Milti-center, Open-Label Study of Tremelimumab Monotherapy in Patients WIth Advanced Solid Tumors
Site Link
NCT02527434
Malignancy
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
Stage
Stage 4
Disease Setting
M
Line Of Therapy
2nd
Investigational Agent
Tremelimumab (and Durvalumab)
Drug Class
anti CTLA-4 antibody (and anti PD-L1 antibody)
PI
Ari VanderWalde, MD, MPH
Sponsor
AstraZeneca
Phase
Phase 1
Status
Closed to Accrual
Key Eligibility Criteria
NCT02527434
Key Eligibility Criteria Details
    • Metastatic Pancreatic Ductal Carcinoma
    • Failed exactly 1 line of prior therapy for metastatic disease
    • No active CNS disease
    • No history of leptomeningeal disease
    • No history of autoimmune disease
Objective
Primary- ORR; Secondary- BOR, DoR, DCR, PFS, OS, Safety
Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
Pancreatic Ductal Carcinoma
Dosing Frequency
Control Agents
Study Protocol
Randomized
No
« back to all trials
View Trial On ClinicalTrials.gov
X